Arthneeti

Novo Nordisk A/S Q1 FY26 Results — Earnings Call Analysis

Published 29 May 2026 | Pharmaceuticals | Market Cap: ₹2.0L Cr

- 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at constant exchange rates, reflecting price declines and market challenges. - International Operations are expected to grow at low single-digit rates, supported by ongoing GLP-1 volume growth and market expansion, despite some patent expiries and increased competition. - U.S. - Novo Nordisk expects adjusted sales growth in 2026 to be between -5% to -13% at constant exchange rates, reflecting pricing headwinds, market dynamics, and competition. - Adjusted operating profit growth for 2026 is also projected in the range of -5% to -13% at constant exchange rates. - Reported growth in Danish kroner is expected to be about 3 percentage points (sales) and 5 percentage points (operating profit) lower than at constant exchange rates due to currency exchange effects. - Sales growth outlook factors in volume expansion in International Operations (mid-single-digit growth), offset by steep price declines and market competition in the U.S.

From Novo Nordisk A/S's Q1 FY26 earnings-call transcript · updated 29 May 2026.

Price

₹45.51

Market Cap

₹2.0L Cr

P/E Ratio

10.4

Revenue Rank

Rank 4

Margin Rank

Rank 4

How does Novo Nordisk A/S rank in Pharmaceuticals?

Compare Novo Nordisk A/S against every Pharmaceuticals company this quarter on revenue, margins and earnings-call signals.

Revenue: Rank 4Margin: Rank 4
View Pharmaceuticals leaderboard →

📊 Revenue & Sales Performance

Rank 4
  • →2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at constant exchange rates, reflecting price declines and market challenges.
  • →International Operations are expected to grow at low single-digit rates, supported by ongoing GLP-1 volume growth and market expansion, despite some patent expiries and increased competition.
  • →U.S. operations anticipate a significant sales decline in the teens, driven primarily by price reductions, competition, market access investments, and the impact of the Most Favored Nations (MFN) agreement.
  • →The global GLP-1 market is still expanding, with continued volume growth projected due to increased patient reach, particularly in obesity and diabetes care.
  • →Novo Nordisk expects volume expansion to partially offset price declines, especially with the uptake of the Wegovy pill.
  • →Longer-term optimism is linked to the success of products like the Wegovy pill and ongoing regulatory milestones across therapy areas.

📈 Profitability & Margins

Rank 4
  • →Novo Nordisk expects adjusted sales growth in 2026 to be between -5% to -13% at constant exchange rates, reflecting pricing headwinds, market dynamics, and competition.
  • →Adjusted operating profit growth for 2026 is also projected in the range of -5% to -13% at constant exchange rates.
  • →Reported growth in Danish kroner is expected to be about 3 percentage points (sales) and 5 percentage points (operating profit) lower than at constant exchange rates due to currency exchange effects.
  • →Sales growth outlook factors in volume expansion in International Operations (mid-single-digit growth), offset by steep price declines and market competition in the U.S. (teens percentage decline).
  • →The company anticipates ongoing investments in market access and volume growth, especially with the Wegovy pill uptake and Medicare coverage improvements starting mid-2026.
  • →Novo Nordisk expects positive free cash flow of DKK 35-45 billion in 2026.
  • →No specific EPS guidance disclosed, but profit outlook aligns with sales and operating profit guidance.

🏗️ Capital Expenditure Plans

Yes
  • →Capital expenditure (CapEx) guidance for 2026 is expected to be around DKK 55 billion.
  • →CapEx investments are focused on manufacturing capacity expansion, including major API (active pharmaceutical ingredient) facilities.
  • →Novo Nordisk expects some new major API facilities to come online during 2026, with more expansions in subsequent years.
  • →Capital expenditure investments are anticipated to decline in the coming years following the finalization of expansion projects.
  • →Over DKK 60 billion was spent on manufacturing capacity expansion through CapEx in 2025.
  • →Novo Nordisk also allocates around DKK 30 billion towards expanding its R&D pipeline through business development.
  • →The company has approved a new share repurchase program of up to DKK 15 billion to be executed over the next 12 months.
  • →Strategic aspirations are being updated, with new plans to be introduced at the Capital Market Day in September 2026.

💰 Fundraising & Capital Structure

No information
- Novo Nordisk has not specifically announced any new fundraising through debt or equity in the provided report. - The company plans capital expenditure (CapEx) around DKK 55 billion in 2026, with expectations for CapEx to decline in coming years following project completions. - They approved a new share repurchase program of up to DKK 15 billion over the next 12 months, indicating a use of capital to return value to shareholders rather than raise new equity. - Cash flow from operations was strong (close to DKK 120 billion in 2025), with significant cash returns to shareholders via dividends and share buybacks. - No explicit mention of issuing new debt or equity for fundraising purposes was made in the call. Overall, Novo Nordisk appears well-capitalized and is focused on organic investments and shareholder returns rather than raising new funds through debt or equity.

📋 Order Book & Pipeline

No information
The provided pages in the PDF do not explicitly mention any details about Novo Nordisk's current or expected orderbook or pending orders. The content focuses primarily on: - Executive management changes and future outlook. - Market growth, especially in obesity and diabetes care. - Launches and uptake of products like Wegovy (pill and injectable). - Guidance for 2026 including sales expectations and strategic priorities. - Supply confidence for Wegovy pill with no anticipated outages in 2026. - Financial metrics such as sales, operating profit, and dividend plans. No direct information related to orderbook or pending order volumes is disclosed in the available transcript.

Key Metrics

Revenue

Rank 4

Margin

Rank 4

Capex

Yes

Fundraise

No information

Order Book

No information

Continue your research

Others in Pharmaceuticals this season

  • Haleon plc (Q1 FY26)

    Haleon plc Q1 FY26 quarterly results analysis. Organic sales growth guidance for 2026 is 3% to 5%, signaling some sequential acceleration from 3% in 2025. Marke

  • Takeda Pharmaceutical Company Limited (Q1 FY26)

    Takeda Pharmaceutical Company Limited Q1 FY26 quarterly results analysis. Growth in plasma-derived therapies (PDT) expected to be mid-single-digit growth for th

  • Sanofi (Q1 FY26)

    Sanofi Q1 FY26 quarterly results analysis. For 2026, Sanofi expects sales to grow by a high single-digit percentage and business EPS to grow slightly faster tha

  • Novartis AG (Q1 FY26)

    Novartis AG Q1 FY26 quarterly results analysis. Novartis expects low single-digit sales growth in 2026 despite significant patent expiries and generic competiti

Compare:vs AstraZeneca PLCvs Johnson & Johnsonvs Novartis AG

Frequently Asked Questions

What were Novo Nordisk A/S Q1 FY26 results?

- 2026 sales growth is expected to be negative, with adjusted sales growth projected at -5% to -13% at constant exchange rates, reflecting price declines and market challenges. - International Operations are expected to grow at low single-digit rates, supported by ongoing GLP-1 volume growth and market expansion, despite some patent expiries and increased competition. - U.S. - Novo Nordisk expects adjusted sales growth in 2026 to be between -5% to -13% at constant exchange rates, reflecting pricing headwinds, market dynamics, and competition. - Adjusted operating profit growth for 2026 is also projected in the range of -5% to -13% at constant exchange rates. - Reported growth in Danish kroner is expected to be about 3 percentage points (sales) and 5 percentage points (operating profit) lower than at constant exchange rates due to currency exchange effects. - Sales growth outlook factors in volume expansion in International Operations (mid-single-digit growth), offset by steep price declines and market competition in the U.S.

What is Novo Nordisk A/S share price analysis?

Novo Nordisk A/S currently shows a neutral. The stock trades at a P/E of 10.4 with a market cap of $203,202. Investors should review the full earnings analysis for detailed insights.

Is Novo Nordisk A/S planning capital expenditure?

- Capital expenditure (CapEx) guidance for 2026 is expected to be around DKK 55 billion.

Keep Novo Nordisk A/S on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.